Gilead Sciences (GILD) Intangibles (2009 - 2026)

Gilead Sciences (GILD) reported Intangibles of $16.4 billion for Q1 2026, down 15.36% on a YoY basis from $19.4 billion in Q1 2025, and down 3.51% quarter-over-quarter from $17.0 billion in Q4 2025.

Gilead Sciences (GILD) Intangibles (2009 - 2026) Analysis & Trends

Gilead Sciences has reported Intangibles for 18 years, with the latest figure at $16.4 billion in Q1 2026.

  • For the quarter ending Q1 2026, Intangibles fell 15.36% year-over-year to $16.4 billion; the trailing twelve-month figure through Mar 2026 stood at $16.4 billion (down 15.36% YoY), and the FY2025 full-year result was $17.0 billion, down 14.89% from the prior year.
  • Intangibles for Q1 2026 stood at $16.4 billion, down from $17.0 billion in the prior quarter.
  • The five-year high for Intangibles was $30.3 billion in Q1 2022, with the low at $16.4 billion in Q1 2026.
  • Historically, Intangibles has averaged $23.8 billion across 5 years, with a median of $23.4 billion in 2024.
  • Annual changes were most pronounced in 2023 — Intangibles slipped 6.54% — and 2024, when it dropped 24.59%.
  • Gilead Sciences' Intangibles stood at $28.9 billion in 2022, then retreated by 8.44% to $26.5 billion in 2023, then dropped by 24.59% to $19.9 billion in 2024, then declined by 14.89% to $17.0 billion in 2025, then declined by 3.51% to $16.4 billion in 2026.
  • The last three Intangibles figures came in at $16.4 billion (Q1 2026), $17.0 billion (Q4 2025), and $18.0 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 24.45 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.37 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 49.06 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 50.87 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 25.75 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 21.38 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 16.38 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 52.56 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 18.24 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn - 10.60 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 16.38 Bn
Dec 31, 2025 16.98 Bn
Sep 30, 2025 17.97 Bn
Jun 30, 2025 18.57 Bn
Mar 31, 2025 19.36 Bn
Dec 31, 2024 19.95 Bn
Sep 30, 2024 20.55 Bn
Jun 30, 2024 22.83 Bn
Mar 31, 2024 23.43 Bn
Dec 31, 2023 26.45 Bn
Sep 30, 2023 27.15 Bn
Jun 30, 2023 27.75 Bn
Mar 31, 2023 28.35 Bn
Dec 31, 2022 28.89 Bn
Sep 30, 2022 29.44 Bn
Jun 30, 2022 29.89 Bn
Mar 31, 2022 30.33 Bn
Dec 31, 2021 33.46 Bn
Sep 30, 2021 33.90 Bn
Jun 30, 2021 34.34 Bn